MCID: PRG090
MIFTS: 30

Progressive Relapsing Multiple Sclerosis

Categories: Neuronal diseases

Aliases & Classifications for Progressive Relapsing Multiple Sclerosis

MalaCards integrated aliases for Progressive Relapsing Multiple Sclerosis:

Name: Progressive Relapsing Multiple Sclerosis 12 14
Multiple Sclerosis, Progressive Relapsing 69
Progressive-Relapsing Ms 12
Prms 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050785
MeSH 42 D020528
SNOMED-CT 64 230374002
UMLS 69 C0393666

Summaries for Progressive Relapsing Multiple Sclerosis

Disease Ontology : 12 A multiple sclerosis that is characterized by steadily worsening symptoms and attacks during periods of remission with disease progression from the onset.

MalaCards based summary : Progressive Relapsing Multiple Sclerosis, also known as multiple sclerosis, progressive relapsing, is related to encephalitis and japanese encephalitis. An important gene associated with Progressive Relapsing Multiple Sclerosis is FCN1 (Ficolin 1), and among its related pathways/superpathways are Immune response Lectin induced complement pathway and Creation of C4 and C2 activators. The drugs Interferon beta-1b and Interferon beta-1a have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and brain.

Related Diseases for Progressive Relapsing Multiple Sclerosis

Diseases related to Progressive Relapsing Multiple Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 18)
id Related Disease Score Top Affiliating Genes
1 encephalitis 10.2
2 japanese encephalitis 10.1
3 tick-borne encephalitis 10.0
4 pericardium disease 9.9 FCN1 MASP2
5 adams-oliver syndrome 9.9 MASP1 MASP2
6 vaccinia 9.8
7 west nile virus 9.8
8 murray valley encephalitis 9.8
9 rhabdomyosarcoma 9.7
10 osteoporosis 9.7
11 osteoarthritis 9.7
12 louping ill 9.7
13 st. louis encephalitis 9.7
14 leiomyoma 9.7
15 avoidant personality disorder 9.6 PGR PRM2
16 lymphangioma 9.6 MASP1 MASP2
17 endogenous depression 9.4 FCN1 FCN2 FCN3 MASP2
18 persistent mullerian duct syndrome 6.5 ATN1 FCN1 FCN2 FCN3 MASP1 MASP2

Graphical network of the top 20 diseases related to Progressive Relapsing Multiple Sclerosis:



Diseases related to Progressive Relapsing Multiple Sclerosis

Symptoms & Phenotypes for Progressive Relapsing Multiple Sclerosis

Drugs & Therapeutics for Progressive Relapsing Multiple Sclerosis

Drugs for Progressive Relapsing Multiple Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 155)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Interferon beta-1b Approved Phase 4,Phase 3,Phase 2 145155-23-3
2
Interferon beta-1a Approved, Investigational Phase 4,Phase 3,Phase 2 145258-61-3 6438354
3
Mitoxantrone Approved, Investigational Phase 4,Phase 3 65271-80-9 4212
4
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
5
Natalizumab Approved, Investigational Phase 4,Phase 3,Phase 1 189261-10-7
6
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
7
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
8
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3 624-49-7 5271565 637568
9 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2
10 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
12 Interferon-beta Phase 4,Phase 3,Phase 2,Phase 1
13 interferons Phase 4,Phase 3,Phase 2,Phase 1
14 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15 Fingolimod Hydrochloride Phase 4,Phase 3
16 Analgesics Phase 4,Phase 3,Phase 2
17 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
18 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2
19 Antiemetics Phase 4,Phase 3
20 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
22 Autonomic Agents Phase 4,Phase 3
23 Gastrointestinal Agents Phase 4,Phase 3
24 glucocorticoids Phase 4,Phase 3,Phase 2
25 Hormone Antagonists Phase 4,Phase 3,Phase 2
26 Hormones Phase 4,Phase 3,Phase 2
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
28 Methylprednisolone acetate Phase 4,Phase 3
29 Methylprednisolone Hemisuccinate Phase 4,Phase 3
30 Neuroprotective Agents Phase 4,Phase 3,Phase 2
31 Prednisolone acetate Phase 4,Phase 3
32 Prednisolone hemisuccinate Phase 4,Phase 3
33 Prednisolone phosphate Phase 4,Phase 3
34 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Dermatologic Agents Phase 4,Phase 3,Early Phase 1
36
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
37
4-Aminopyridine Approved Phase 3 504-24-5 1727
38
Morphine Approved, Investigational Phase 3 57-27-2 5288826
39
Glatiramer Acetate Approved, Investigational Phase 3 147245-92-9 3081884
40 Neurotransmitter Agents Phase 3,Phase 2,Phase 1
41 Alkylating Agents Phase 3,Phase 2
42 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Early Phase 1
43 Potassium Channel Blockers Phase 3
44 Vaccines Phase 2, Phase 3,Phase 1
45 Adrenocorticotropic Hormone Phase 3,Phase 2
46 beta-endorphin Phase 3,Phase 2
47 Melanocyte-Stimulating Hormones Phase 3,Phase 2
48 Endorphins Phase 3
49
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
50
Daclizumab Approved, Investigational Phase 2,Phase 1 152923-56-3

Interventional clinical trials:

(show top 50) (show all 100)

id Name Status NCT ID Phase Drugs
1 Effect of Interferon Beta-1a (Avonex®) on Changes of Non-Conventional MRI Measures in Patients With MS Completed NCT00463710 Phase 4 Avonex® monotherapy (6.0 MIU administered i.m. each week)
2 Long-term Follow-up of Fingolimod Phase II Study Patients Completed NCT02307838 Phase 4
3 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
4 Methylprednisolone During the Switch Between Natalizumab and Fingolimod Recruiting NCT02769689 Phase 4 Methylprednisolone;Placebo;natalizumab (NTZ);fingolimob (FTY)
5 Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate Recruiting NCT02901106 Phase 4 Dimethyl fumarate
6 Safety and Effectiveness of Switching Relapsing MS Patients Treated With Natalizumab at Risk for PML to Teriflunomide Active, not recruiting NCT01970410 Phase 4 teriflunomide
7 Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients Active, not recruiting NCT03092544 Phase 4 dimethyl fumarate
8 Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis Terminated NCT01411514 Phase 4 Prednisone;Placebo
9 Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis Terminated NCT01701856 Phase 4 Interferon beta-1b
10 Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis Terminated NCT01490840 Phase 4
11 Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis Completed NCT00134563 Phase 3 Teriflunomide;Placebo (for teriflunomide)
12 Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis Completed NCT00241254 Phase 3 Cyclophosphamide (drug);Methylprednisolone (drug)
13 A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis Completed NCT01917019 Phase 3 Placebo;BIIB041 (fampridine)
14 A Study for Patients With Secondary Progressive Multiple Sclerosis Completed NCT00869726 Phase 2, Phase 3 dirucotide;Placebo
15 Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS) Recruiting NCT02688985 Phase 3 Ocrelizumab
16 A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis Recruiting NCT01433497 Phase 2, Phase 3 masitinib;placebo
17 Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study Active, not recruiting NCT00273364 Phase 3 Standard treatment with a conventional drug
18 Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) Active, not recruiting NCT01665144 Phase 3 BAF312;Placebo
19 Effects of Acthar on Recovery From Cognitive Relapses in MS Enrolling by invitation NCT02290444 Phase 3 Adrenocorticotropic Hormone
20 A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis Not yet recruiting NCT02057159 Phase 2, Phase 3
21 BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis Terminated NCT02430532 Phase 3 dimethyl fumarate
22 Study Evaluating Mitoxantrone in Multiple Sclerosis Terminated NCT00146159 Phase 3 Mitoxantrone
23 Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis Terminated NCT00468611 Phase 3 MBP8298
24 A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis Terminated NCT01416181 Phase 3 natalizumab;Placebo
25 Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS) Withdrawn NCT00313976 Phase 3 Interferon beta-1b (Betaferon/Betaseron, BAY86-5046);Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
26 Combination Therapy of Betaseron-Prograf in Multiple Sclerosis Unknown status NCT00298662 Phase 2 Interferon beta-1b and Tacrolimus
27 T Cell Vaccination in Patients With Progressive Multiple Sclerosis Completed NCT01448252 Phase 1, Phase 2
28 Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses Completed NCT00228163 Phase 2 teriflunomide (HMR1726)
29 Masitinib in Patients With Primary Progressive Multiple Sclerosis (PPMS) or Relapse-free Secondary Progressive Multiple Sclerosis (SPMS) Completed NCT01450488 Phase 2 masitinib;masitinib
30 Progressive Muscle Relaxation Effect on Sleep Quality, Depression and Stress in People With Multiple Sclerosis Completed NCT02673827 Phase 2
31 Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS) Completed NCT00079495 Phase 2 NBI-5788
32 Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis Completed NCT00587691 Phase 1, Phase 2
33 Treatment of Multiple Sclerosis Using Over the Counter Inosine Completed NCT00067327 Phase 2 Inosine
34 Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis Completed NCT00071838 Phase 2 Daclizumab
35 Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple Sclerosis Completed NCT01377870 Phase 1, Phase 2
36 High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study Completed NCT00288626 Phase 2 Granulocyte-colony stimulating factor (G-CSF) and prednisone;Carmustine, etoposide, cytarabine, and melphalan (BEAM)
37 A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD) Completed NCT00436826 Phase 2 Cladribine;Placebo;Interferon-beta (IFN-beta)
38 Immunological Mechanisms of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Completed NCT00342134 Phase 2
39 A Cooperative Clinical Study of Abatacept in Multiple Sclerosis Completed NCT01116427 Phase 2 Placebo
40 Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS) Completed NCT00086671 Phase 2 ABT-874/Human monoclonal antibody against IL-12;Placebo
41 ACTH in Progressive Forms of MS Recruiting NCT01950234 Phase 2 ACTH;Placebo
42 Safety and Tolerability of Quetiapine in Multiple Sclerosis Recruiting NCT02087631 Phase 1, Phase 2 Extended-release quetiapine fumarate
43 Assessment of Bone Marrow-derived Cellular Therapy in Progressive Multiple Sclerosis (ACTiMuS) Recruiting NCT01815632 Phase 2
44 Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition Recruiting NCT01466114 Phase 2 estriol;Norethindrone
45 Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis Recruiting NCT02988401 Phase 1, Phase 2 Insulin;Placebo
46 Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease Recruiting NCT02649985 Phase 1, Phase 2 [F-18]PBR06
47 Protective Role of Oxcarbazepine in Multiple Sclerosis Recruiting NCT02104661 Phase 2 Oxcarbazepine;Placebo
48 Autologous Mesenchymal Stromal Cells for Multiple Sclerosis Active, not recruiting NCT02495766 Phase 1, Phase 2 XCEL-MC-ALPHA;Placebo
49 MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial Active, not recruiting NCT01910259 Phase 2 Amiloride;Riluzole;Fluoxetine;Placebo
50 Double Blind Placebo-Controlled Phase I/II Clinical Trial of Idebenone in Patients With Primary Progressive Multiple Sclerosis (IPPoMS) Active, not recruiting NCT00950248 Phase 1, Phase 2 Idebenone

Search NIH Clinical Center for Progressive Relapsing Multiple Sclerosis

Genetic Tests for Progressive Relapsing Multiple Sclerosis

Anatomical Context for Progressive Relapsing Multiple Sclerosis

MalaCards organs/tissues related to Progressive Relapsing Multiple Sclerosis:

39
T Cells, Bone, Brain, B Cells, Spinal Cord

Publications for Progressive Relapsing Multiple Sclerosis

Articles related to Progressive Relapsing Multiple Sclerosis:

id Title Authors Year
1
Clinical characteristics of progressive relapsing multiple sclerosis. ( 15327045 )
2004
2
A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis. ( 12749517 )
2003

Variations for Progressive Relapsing Multiple Sclerosis

Expression for Progressive Relapsing Multiple Sclerosis

Search GEO for disease gene expression data for Progressive Relapsing Multiple Sclerosis.

Pathways for Progressive Relapsing Multiple Sclerosis

GO Terms for Progressive Relapsing Multiple Sclerosis

Cellular components related to Progressive Relapsing Multiple Sclerosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 collagen trimer GO:0005581 8.8 FCN1 FCN2 FCN3

Biological processes related to Progressive Relapsing Multiple Sclerosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.8 FCN1 FCN2 FCN3 MASP1 MASP2 NOD1
2 proteolysis GO:0006508 9.77 FCN1 FCN2 FCN3 MASP1 MASP2
3 immune system process GO:0002376 9.73 FCN1 FCN2 FCN3 MASP1 MASP2 NOD1
4 defense response to Gram-positive bacterium GO:0050830 9.43 FCN2 NOD1
5 negative regulation of viral entry into host cell GO:0046597 9.4 FCN1 FCN3
6 complement activation GO:0006956 9.35 FCN1 FCN2 FCN3 MASP1 MASP2
7 recognition of apoptotic cell GO:0043654 9.33 FCN1 FCN2 FCN3
8 complement activation, lectin pathway GO:0001867 9.02 FCN1 FCN2 FCN3 MASP1 MASP2

Molecular functions related to Progressive Relapsing Multiple Sclerosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 ATN1 FCN1 FCN2 FCN3 MASP1 MASP2
2 carbohydrate binding GO:0030246 9.33 FCN1 FCN2 FCN3
3 calcium-dependent protein binding GO:0048306 9.13 FCN2 MASP1 MASP2
4 serine-type endopeptidase activity GO:0004252 9.02 FCN1 FCN2 FCN3 MASP1 MASP2

Sources for Progressive Relapsing Multiple Sclerosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....